Company intelligence / Profile preview

EnginZyme

Stockholm, Sweden

Ownership: Private
Employees: ~30
Development stage: Other

Overview

EnginZyme’s core enzyme immobilization technology enables efficient, scalable cell-free biomanufacturing for APIs, intermediates, and chemicals, with demonstrated energy and cost reductions versus conventional fermentation. Commercial chemical synthesis projects have validated multi-enzyme cascades. No clinical data as company is not developing drugs directly, but enabling sustainable manufacturing for pharma and chemicals

Therapeutic areas: Other
Modalities: EnzymeBiocatalystRecombinant protein
Industry: Non-Drug Biotech

Partnerships

Tetra Pak

Beyond the preview

Go deeper on EnginZyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnginZyme.

Explore the full profile